利妥昔单抗与他克莫司在儿童激素依赖性肾病综合征中的疗效比较:一项随机临床试验
该平行组、开放标签、单中心随机临床试验纳入120例既往未使用激素节约剂的激素依赖性肾病综合征患儿,比较单疗程利妥昔单抗(2次375 mg/m2输注)与他克莫司(联合隔日泼尼松龙减量)治疗12个月的疗效。结果显示利妥昔单抗组12个月无复发生存率显著高于他克莫司组(90.0% vs 63.3%,P < .001),且累积激素剂量更低、轻度至中度感染更少。
要点
- 利妥昔单抗12个月无复发生存率90.0%,显著优于他克莫司63.3%(P < .001)。
- 利妥昔单抗组12个月累积泼尼松龙剂量低于他克莫司组(25.8 vs 86.3 mg/kg)。
- 他克莫司组轻度至中度感染事件约为利妥昔单抗组两倍(43.3% vs 21.7%)。
核心结论
- 在激素依赖性肾病综合征患儿中,利妥昔单抗在维持缓解和减少激素暴露方面似乎优于他克莫司。
- 鉴于利妥昔单抗耐受性良好且无肾毒性,可考虑作为一线激素节约治疗。
研究设计与样本
- 平行组、开放标签、随机临床试验,2015年5月8日至2016年9月20日单中心三级医疗单位开展,随访1年。
- 筛查176例3至16岁既往未使用激素节约剂的激素依赖性肾病综合征患儿,随机化120例,除3例外均完成1年随访。
- 干预为他克莫司联合隔日泼尼松龙减量治疗12个月,或单疗程利妥昔单抗(2次375 mg/m2输注)。
- 主要结局为意向性治疗人群的12个月无复发生存率。
主要发现
- 利妥昔单抗组12个月无复发生存率高于他克莫司组(54例[90.0%] vs 38例[63.3%];P < .001;比值比5.21;95% CI 1.93-14.07)。
- 复发患者中,利妥昔单抗组首次复发中位时间40周,他克莫司组29周。
- 研究期间利妥昔单抗组仅2例复发超过1次,他克莫司组为10例。
- 12个月研究期间累积皮质激素剂量利妥昔单抗组低于他克莫司组(均值[SD] 25.8[27.8] vs 86.3[58.0] mg/kg)。
- 两种治疗均耐受良好,但他克莫司组轻度至中度感染事件为利妥昔单抗组两倍(26[43.3%] vs 13[21.7%]事件)。
关键数值与推荐
- 纳入标准为3至16岁激素依赖性肾病综合征患儿,既往未接受激素节约剂治疗。
- 利妥昔单抗给药方案为单疗程2次375 mg/m2输注。
- 他克莫司治疗12个月并联合隔日泼尼松龙减量。
临床怎么用
- 对于既往未使用激素节约剂的激素依赖性肾病综合征患儿,可考虑将利妥昔单抗作为一线激素节约治疗选择。
- 利妥昔单抗单疗程可显著降低12个月累积激素剂量,并减少轻度至中度感染事件。
局限性
- 单中心、开放标签设计可能引入偏倚。
- 随访时间仅1年,长期疗效与安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Calcineurin inhibitors are an established first-line corticosteroid-sparing therapy for patients with corticosteroid-dependent nephrotic syndrome (CDNS), whereas B-lymphocyte-depleting therapy is mostly used as a rescue for calcineurin inhibitor-resistant cases. The positive efficacy and safety profile of rituximab raises the question of whether it could be used as a first-line alternative to calcineurin inhibitor therapy. OBJECTIVE: To compare the efficacy of rituximab and tacrolimus in maintaining relapse-free survival among children with CDNS. DESIGN, SETTING, AND PARTICIPANTS: A parallel-arm, open-label, randomized clinical trial was performed from May 8, 2015, to September 20, 2016, with 1-year follow-up in a single-center, tertiary care unit. A total of 176 consecutive children aged 3 to 16 years with CDNS not previously treated with corticosteroid-sparing agents were screened for eligibility. INTERVENTIONS: The children received either tacrolimus (along with tapering alternate-day prednisolone) for 12 months or a single course of rituximab (2 infusions of 375 mg/m2). MAIN OUTCOMES AND MEASURES: Twelve-month relapse-free survival in the intention-to-treat population. RESULTS: Of the 176 children screened for eligibility, 120 were randomized and all but 3 patients completed 1 year of follow-up. The groups were comparable, with mean (SD) age of 7.2 (2.8) years, 32 boys (53.3%) in each group, mean (SD) disease duration of 2.5 (1.5) years and 2.3 (1.7) in the tacrolimus and rituximab groups, respectively, disease duration less than 1 year among 15 children (25.0%) in each group, median (interquartile range) of 4 (3-5) relapses in each group, and mean (SD) cumulative prednisolone dose of 246 (48) mg/kg and 239 (52) mg/kg in the prestudy year in the tacrolimus and rituximab groups, respectively. Rituximab therapy was associated with a higher 12-month relapse-free survival rate than tacrolimus (54 [90.0%] vs 38 [63.3%] children; P < .001; odds ratio, 5.21; 95% CI, 1.93-14.07). Among the patients who experienced relapse, median time to first relapse was 40 weeks in the rituximab group and 29 weeks in the tacrolimus group. Only 2 patients in the rituximab group had more than 1 relapse during the study period compared with 10 patients in the tacrolimus group. The cumulative corticosteroid dose during the 12-month study period was lower with rituximab compared with tacrolimus (mean [SD], 25.8 [27.8] vs 86.3 [58.0] mg/kg). Although both treatments were well tolerated, mild to moderate infections were twice as common in the tacrolimus group (26 [43.3%] vs 13 [21.7%] events). CONCLUSIONS AND RELEVANCE: In children with CDNS, rituximab appears to be more effective than tacrolimus in maintaining disease remission and minimizing corticosteroid exposure and, given its good tolerability and lack of nephrotoxic effects, may be considered as first-line corticosteroid-sparing therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02438982; Clinical Trial Registry of India: CTRI/2014/01/004355.
引用
- Basu B, Sander A, Roy B, et al. Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. JAMA Pediatr. 2018. PMID: 29913001. doi:10.1001/jamapediatrics.2018.1323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。